{"entity":{"id":"il2rb","kind":"target","name":"IL2RB","aka":["interleukin 2 receptor subunit beta","Interleukin-2 receptor subunit beta","CD122","IL15RB"],"tldr":"IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.","summary":"Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15.\n\nOpen Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.84, animal model 0.52, genetic association 0.00, clinical 0.96). In OnCo, 1 product record names it (Bempegaldesleukin).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:6009","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6009"},{"label":"UniProt P14784","url":"https://www.uniprot.org/uniprotkb/P14784/entry"},{"label":"NCBI Gene 3560","url":"https://www.ncbi.nlm.nih.gov/gene/3560"},{"label":"Ensembl ENSG00000100385","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100385"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["skin-cancer","leukaemia","rcc","non-hodgkin-lymphoma","cutaneous-t-cell-lymphoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["bempegaldesleukin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"IL2RB","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:6009","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6009","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P14784","url":"https://www.uniprot.org/uniprotkb/P14784/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000100385","url":"https://platform.opentargets.org/target/ENSG00000100385/associations","note":"association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: renal cell carcinoma 0.52, melanoma 0.55, non-Hodgkin lymphoma 0.51, skin cancer 0.56, leukaemia 0.53, primary cutaneous T-cell non-Hodgkin lymphoma 0.55 (GraphQL API, CC0)"}],"specificity":"lineage-antigen","distribution":"few-types","specificityNote":"Lineage antigen shared with normal NK-cells and T-cells and bone marrow cells and lymphoid tissue cells: HPA finds the gene tissue enhanced in bone marrow, lymphoid tissue, and the 1 medicine aimed at it (Bempegaldesleukin) act on the wild-type protein, so the normal lineage is hit too. HPA IL2RB: RNA tissue enhanced (bone marrow 33 nTPM, lymphoid tissue 46 nTPM); blood lineage group enriched (NK-cells 184 nTPM, T-cells 50 nTPM); no normal tissue stained high. Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Leukaemia, Renal cell carcinoma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (primary cutaneous T-cell non-Hodgkin lymphoma, renal cell carcinoma). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas IL2RB tissue","url":"https://www.proteinatlas.org/ENSG00000100385-IL2RB/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas IL2RB pathology","url":"https://www.proteinatlas.org/ENSG00000100385-IL2RB/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000100385 associations","url":"https://platform.opentargets.org/target/ENSG00000100385/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:6009","ensembl":"ENSG00000100385","uniprot":"P14784","entrez":"3560","firstDescribed":1989,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Hatakeyama et al, Science, 1989, \"Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2785715/","biology":"Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. Location: Cell membrane (UniProt). Locus 22q12.3 (HGNC).","whereFound":["Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)","Leukaemia: Open Targets association 0.53 with leukaemia (MONDO_0005059)","Renal cell carcinoma: Open Targets association 0.52 with renal cell carcinoma (MONDO_0005086)","Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908)","Cutaneous T-cell lymphoma: Open Targets association 0.55 with primary cutaneous T-cell non-Hodgkin lymphoma (MONDO_0000607)","Melanoma: Open Targets association 0.55 with melanoma (MONDO_0005105)"],"targetClass":"other","prevalence":[]},"route":"/targets/il2rb/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"drug":[{"id":"bempegaldesleukin","kind":"drug","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/"}]}}